New Delhi, Aug 5 (IANS) A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer, according to researchers.
Researchers from the University of Sheffield show that this new immunotherapy could extend the period before prostate cancer becomes resistant to hormone therapy.
For many men diagnosed with prostate cancer, androgen deprivation therapy (ADT) is a powerful first-line treatment. However, in some cases, tumours develop resistance to ADT, causing the cancer to spread and become incurable.
While immunotherapy has had success in treating other cancers, it has not been as effective for prostate cancer.
Researchers aimed to understand why and developed a novel approach. Using cutting-edge techniques, they studied immune cell function within prostate tumours post-ADT, leading to an innovative way to deliver immunotherapy.
Published in the Journal for Immunotherapy of Cancer, the study is the first to show that carefully designed nanoparticles can stimulate T cells to attack cancer cells, significantly delaying resistance to ADT.
Study leader, Professor Claire Lewis, from the University of Sheffield’s School of Medicine and Population Health, said: “The onset of resistance to hormone therapy is a major clinical problem in treating men with prostate cancer. Their tumours start to regrow and spread, making the disease difficult to treat.”
The research revealed that macrophages, a type of white blood cell, accumulate around blood vessels in prostate tumours during ADT. Researchers then developed nanoparticles to deliver a drug to these cells, causing them to express interferon-beta, a potent immunostimulant. This stimulates T cells to kill cancer cells, delaying treatment resistance.
Dr Hayley Luxton, Research Impact Manager at Prostate Cancer UK, said: “Over 12,000 men die from prostate cancer each year in the UK. Immunotherapy has transformed other cancer treatments but hasn’t yet seen similar success for prostate cancer.”
The study offers hope that this new form of immunotherapy could enhance the response to hormone treatment and delay resistance, potentially changing the outlook for prostate cancer patients.
–IANS
ts/vd
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
